Joshua Yang, MD

Growth Hormone Deficiency in Cancer Survivors 

In the final episode, the panel addresses one of the most clinically complex and emotionally charged questions in GHD management: when and how to initiate or resume GH therapy in patients with a history of malignancy.

Dr. Agrawal poses the question of GH use in the setting of active or recent malignancy, noting that in adult practice, the standard approach is to wait at least 5 years post-remission before initiating GH — with a multidisciplinary decision involving the oncology team. One exception is non-melanoma skin cancers, which are considered lower-risk for GH-related stimulation.

Dr. Alter explains the pediatric approach, which is institution-dependent and individualized. At Children’s Hospital of Philadelphia, for non-craniopharyngioma malignancies (e.g., germ cell tumors), the team waits 2 years from tumor stability, documents neuro-oncology consensus, and monitors with MRI at 6-month intervals. For craniopharyngiomas, evidence now supports initiating GH as early as 6 months post-treatment, given that no excess tumor recurrence risk has been observed. Age matters: a 3-year-old has more time to wait; a 14-year-old in a critical growth window may not.

Dr. Garcia frames the informed consent conversation for adult cancer survivors: patients must understand that having a prior malignancy (and its treatments, including radiation) already elevates the risk of secondary cancers — and that current data do not show GH adding further risk beyond that baseline. However, these conversations must acknowledge genuine uncertainty, and patients must be active partners in the decision.

Thank you for watching this HCP Live Peer Exchange series on growth hormone deficiency. Please subscribe to our eNewsletter for information on upcoming video series.

Videos

Experts debate when to start growth hormone after cancer, share pediatric vs adult wait times, and offer tips on long‑acting GH dosing.

Growth Hormone Deficiency in Cancer Survivors

Navigating Barriers in Adult GHD Management

This episode focuses on the real-world access challenges that clinicians and patients with adult GHD face — including insurance denials, documentation requirements, and strategies for obtaining and sustaining GH therapy approvals.

Dr. Agrawal opens with a frank observation: insurance companies frequently do not understand adult GHD. The term “growth hormone” creates conceptual confusion for payers who associate GH exclusively with childhood height. She suggests that adult GHD might benefit from reframing — as a metabolic disease, for example — to help payers understand its systemic and long-term health implications. Until then, comprehensive documentation aligned with FDA indications and clinical guidelines remains the clinician’s primary tool.

Practical documentation strategies discussed by the panel include: citing FDA-approved indications explicitly in clinical notes, including all pediatric GH history and testing when available, compiling a complete prior authorization package that tells a coherent clinical narrative, and in some cases requiring patients to demonstrate failure on daily GH before gaining insurance approval for weekly analogs.

Dr. Garcia underscores that a formal transition clinic would be the ideal solution for documentation continuity — with all records centralized and specialists from both sides co-present. He confirms that most of his transitioning patients arrive with adequate prior testing in place, reducing the need for complete retesting.

The episode closes with a broader discussion on optimizing long-term adult GHD care. Dr. Garcia stresses the value of patient engagement: understanding what matters to each patient — whether fatigue, mood, body composition, or general wellbeing — and framing treatment goals around those priorities dramatically improves adherence. Dr. Yang reinforces that GHD is not simply a growth condition that ends in adulthood; some of the most serious metabolic and skeletal consequences can emerge or worsen in adult years.

,” the panel tackles GH use in patients with active or prior malignancy.

Insurance barriers and missing records complicate adult growth hormone therapy, as experts urge better documentation, transition clinics, and patient-centered care to improve outcomes.

Transitioning GHD Patients from Pediatric to Adult Care — Challenges and Best Practices

This episode addresses transition of care in GHD — widely recognized as one of the most clinically vulnerable periods for patients, with high rates of dropout and delayed or lost treatment.

Dr. Alter identifies the fundamental challenge from the pediatric side: finding adult endocrinologists with pituitary disease expertise and availability. Wait times for established pituitary specialists can stretch up to a year. His institution works proactively to cultivate relationships with adult endocrinologists across the Philadelphia region to ensure continuity.

Dr. Agrawal describes NYU’s collaborative approach: pediatric colleagues begin flagging patients for potential adult GH therapy as early as age 11–12, aiming for a smooth transition around ages 14–15. This advance communication allows time for retesting decisions, insurance prior authorizations, and documentation to be completed before treatment gaps occur.

A major concern raised by both Dr. Agrawal and Dr. Garcia is patient dropout. Patients who have formed trusted relationships with their pediatric endocrinologists are often reluctant to transfer care, and many are simply lost to follow-up. Those with structural pituitary disease face the most serious consequences if GH therapy lapses — including progressive weight gain, bone loss, and lean mass depletion.

The panel stresses the importance of beginning conversations about the adult role of GH early — before the patient stops growing. Patients often assume GHD ends with growth, so educating them that GH continues to support bone accrual (which peaks in the mid-20s) and body composition into adulthood is essential to sustaining motivation.

The panel recommends structured tools to facilitate transitions: patient handouts summarizing GH history and test results, and ideally a joint pediatric-adult transition clinic — a model not yet widely implemented but recognized as the gold standard.

Navigating Insurance, Documentation, and Access Barriers in Adult GHD Management

,” the panel examines the practical obstacles clinicians face in getting adult GHD therapy authorized and sustained, and strategies for overcoming them.

How to keep growth hormone deficiency patients on track when moving to adult care—cutting waitlists, dropouts, and insurance delays.

Dosing and Managing Long-Acting GH Therapy in Adults — Clinical Factors, Titration, and Side Effects

This episode examines adult-specific dosing and management strategies for long-acting GH analogs, with attention to clinical factors that guide formulation selection, titration targets, and the management of side effects more common in adults than children.

Dr. Garcia and Dr. Agrawal outline their approach to selecting between daily and weekly GH in adult patients. In an ideal world, patient preference and adherence would be the primary drivers. Dr. Garcia describes a patient in law enforcement who could not carry needles into a correctional facility — making weekly GH not just preferred but functionally necessary. Dr. Agrawal states she would switch all appropriate adult patients to weekly formulations if insurance access allowed, given the convenience and adherence benefits.

Adult dosing for long-acting analogs is non-weight-based and age-stratified. For somapacitan, the standard adult starting dose is 1.5 mg/week, though clinicians typically initiate lower (e.g., 1 mg/week) and titrate up. Elderly patients (>60–70 years) and those with poorly controlled type 2 diabetes start even lower. Women on oral estrogen (birth control pills) — due to hepatic GH resistance — may require a higher starting dose (2 mg/week). For lonapegsomatropin, dosing tiers of 0.7, 1.4, and 2.1 mg/week are adjusted based on patient age, sex hormone use, and comorbidities.

IGF-1 monitoring in adults should occur at mid-week (day 3–4 for somapacitan; day 4–5 for lonapegsomatropin) to capture the pharmacokinetic midpoint. Target IGF-1 is 0 to +2 standard deviation score above the mean. However, adults frequently experience side effects — particularly edema, arthralgias, and carpal tunnel symptoms — that limit dose escalation before the IGF-1 target is reached.

Dr. Garcia emphasizes the need to assess baseline joint symptoms before initiating GH, since arthralgia is the most common adult side effect and often indistinguishable from pre-existing musculoskeletal complaints.

,” the panel addresses one of the most clinically challenging aspects of GHD management: navigating the handoff from pediatric to adult endocrinology and preventing loss to follow-up.

Clinicians explain practical weekly growth hormone dosing—weight-based, pen-device rounding, and IGF‑1 checks—plus how puberty, fatigue, and growth velocity guide stopping therapy.

Joshua Yang, MD

Articles